(secondQuint)Ablative STEreotactic RadiOtherapy wIth Durvalumab (MEDI4736).

 This is a randomized multicentre open label phase II study of the PDL1 inhibitor Durvalumab following SBRT in patients with T1-2N0M0 NSCLC.

 It will enroll 216 patients aiming at a minimum of 5 subjects per site.

 The subjects will be randomized in a 1:1 fashion with performance status, gender and T-stage as stratification factors.

 Patients with peripheral lung tumors will receive SBRT usually between 3 and 4 fractions.

 The group randomized to immunotherapy will then receive Durvalumab, given with a fixed dose of 1500 mg i.

v.

 every fourth week during 12 months.

 Both arms will be assessed according to the same follow-up schedule with radiology every third month.

.

 Ablative STEreotactic RadiOtherapy wIth Durvalumab (MEDI4736)@highlight

This is a randomized multicentre open label phase II study of Durvalumab following Stereotactic Body Radiotherapy (SBRT) in patients with T1-2N0M0 NSCLC.

 Patients will be randomized 1:1 to follow up or receiving Durvalumab every 4th week for 12 months